Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

Abstract Background Immunotherapy targeting PD-1/PD-L1 fails to induce clinical responses in most patients with solid cancers. N-803, formerly ALT-803, is an IL-15 superagonist mutant and dimeric IL-15RαSushi-Fc fusion protein complex that enhances CD8+ T and NK cell expansion and function and exhib...

Full description

Bibliographic Details
Main Authors: Karin M. Knudson, Kristin C. Hicks, Sarah Alter, Jeffrey Schlom, Sofia R. Gameiro
Format: Article
Language:English
Published: BMJ Publishing Group 2019-03-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
PD-L1
ALT-803
N-803
Tumor microenvironment
Online Access:http://link.springer.com/article/10.1186/s40425-019-0551-y

Internet

http://link.springer.com/article/10.1186/s40425-019-0551-y

Similar Items